Trial · NCT05350202
Results by group113
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 113
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change of the Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores in Patients Newly Treated With Empagliflozin According to Routine Practice | Empagliflozin-treated Patients | CSS | 14.66 | Standard Deviation 18.44 | Units on a scale |
| Change of the Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores in Patients Newly Treated With Empagliflozin According to Routine Practice | Empagliflozin-treated Patients | TSS | 17.61 | Standard Deviation 21.04 | Units on a scale |
| Change of the Kansas City Cardiomyopathy Questionnaire (KCCQ) Scores in Patients Newly Treated With Empagliflozin According to Routine Practice | Empagliflozin-treated Patients | OSS | 16.47 | Standard Deviation 18.86 | Units on a scale |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class II / Week 24 Class I | 337 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class II / Week 24 Class II | 1388 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class II / Week 24 Class III | 54 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class II / Week 24 Class IV | 0 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class II / Unknown | 5 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class II / Missing | 184 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class II / No Week 24 visit | 13 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class III / Week 24 Class I | 37 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class III / Week 24 Class II | 730 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class III / Week 24 Class III | 368 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class III / Week 24 Class IV | 3 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class III / Unknown | 0 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class III / Missing | 118 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class III / No Week 24 visit | 7 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class IV / Week 24 Class I | 0 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class IV / Week 24 Class II | 20 | Participants | |
| Change of the New York Heart Association (NYHA) Class in Patients Newly Treated With Empagliflozin | Empagliflozin-treated Patients | Baseline Class IV / Week 24 Class III | 22 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05350202/results